Renaissance BioScience enters a partnership with Mitacs to test its yeast-based, RNAi production platform for biocontrol and biotherapeutics applications.
Bayer has inked a deal with preclinical CRO Cenix BioScience to use its genome-scale RNA interference (RNAi) platform to target an undisclosed disease.
With Angiomax potentially going generic in 2015, The Medicines Company has collaborated with Alnylam over a 'pragmatic' high cholesterol drug to aid future growth.
RXi and EyeGate lift the lid on ocular delivery of RNAi therapeutics for retinal disorders as the two firm’s team up to provide a unique needle-free solution.
RXi Pharmaceuticals and EyeGate Pharma will unite to develop non-invasive, needle-free ocular delivery of RNAi therapeutics using the EyeGate II system for the treatment of retinal disorders.
New research could make it possible for scientists to use silicon particles as an effective drug delivery system that enables fragile small interfering RNA (siRNA) based drugs to be directly transported to the disease’s location.
MDRNA’s liposomal drug delivery formulation, DiLA2, lost no potency when stored for 12 months in conditions ranging from -80ºC to 4ºC, helping to validate it for administration of UsiRNA.